Paragon Therapeutics Launches First Spinout, Apogee Therapeutics, to Advance Novel Therapies for Inflammatory and Immunological Conditions

Apogee emerges with $169 million to expand team and progress lead program APG777 into the clinic

Milestone validates Paragon's strategy to rapidly deliver best-in-class biologic therapies to patients